Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4967269 | 0.77 | — | — | |
| SCHEMBL7250055 | 0.75 | TDP1 (0.33) | CYP3A4DNM1ALDH1A1ADRB2ADRB1 | |
| SCHEMBL18959857 | 0.75 | CYP3A4 (0.37) | CYP3A4DNM1ALDH1A1ADRB2ADRB1 | |
| SCHEMBL709724 | 0.75 | — | — | |
| SCHEMBL25970008 | 0.74 | — | — | |
| SCHEMBL20995918 | 0.74 | ADRB2 (0.39) | CYP3A4DNM1ALDH1A1ADRB2ADRB1 | |
| SCHEMBL2759867 | 0.74 | — | — | |
| SCHEMBL16079426 | 0.74 | — | — | |
| SCHEMBL9509304 | 0.74 | CYP3A4 (0.30) | CYP3A4 | |
| SCHEMBL7247759 | 0.74 | EPHX2 (0.32) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138837-B1 | INDACATEROL FREE BASE IN SOLID FORM | CRYSTAL PHARMA SAU (ES) | 2021-11-24 | — | — | EP | disclosed |
| EP-3848354-A1 | PROCESS FOR THE PREPARATION OF INDACATEROL AND INTERMEDIATES THEREOF | Crystal Pharma, S.A.U. (ES) | 2021-07-14 | — | — | EP | disclosed |
| US-10040765-B2 | Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof | CRYSTAL PHARMA S.A.U. (ES) | 2018-08-07 | — | — | US | disclosed |
| EP-2897937-B1 | PROCESS FOR THE PREPARATION OF INDACATEROL AND INTERMEDIATES THEREOF | CRYSTAL PHARMA SAU (ES) | 2017-12-06 | — | — | EP | disclosed |
| EP-3138837-A1 | INDACATEROL FREE BASE IN SOLID FORM | Crystal Pharma, S.A.U. (ES) | 2017-03-08 | — | — | EP | disclosed |
| US-20170015628-A1 | METHODS FOR THE PREPARATION OF INDACATEROL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CRYSTAL PHARMA S.A.U. (ES) | 2017-01-19 | — | — | US | disclosed |
| US-9475772-B2 | Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof | CRYSTAL PHARMA S.A.U. (ES) | 2016-10-25 | — | — | US | disclosed |
| US-20150225346-A1 | METHODS FOR THE PREPARATION OF INDACATEROL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CRYSTAL PHARMA S.A.U. (ES) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040765-B2 | Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof | SQLE, HSD11B1, CYP51A1 | CYP3A4 16/4885DNM1 4534/4885ALDH1A1 205/4885 |
| US-20150225346-A1 | METHODS FOR THE PREPARATION OF INDACATEROL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SQLE, HSD11B1, CYP51A1 | CYP3A4 16/4885DNM1 4534/4885ALDH1A1 205/4885 |
| US-20170015628-A1 | METHODS FOR THE PREPARATION OF INDACATEROL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SQLE, HSD11B1, CYP51A1 | CYP3A4 16/4885DNM1 4534/4885ALDH1A1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.